Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.58 |
| ▸ | S1PR5 | Q9H228 | 13/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | GRK5 | P34947 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9110127 | 0.84 | S1PR5 (0.51) | S1PR1S1PR5HTR2AKCNH2SIGMAR1 | |
| SCHEMBL10061464 | 0.79 | S1PR5 (0.69) | S1PR1S1PR5GRK5CDK8 | |
| SCHEMBL10060820 | 0.78 | S1PR1 (0.52) | S1PR1S1PR5 | |
| SCHEMBL10060821 | 0.76 | S1PR1 (0.51) | S1PR1S1PR5 | |
| SCHEMBL3042662 | 0.75 | S1PR5 (1.00) | S1PR1S1PR5HTR2AKCNH2SIGMAR1 | |
| SCHEMBL10061463 | 0.73 | S1PR1 (0.51) | S1PR1S1PR5 | |
| SCHEMBL10060848 | 0.73 | S1PR5 (0.56) | S1PR1S1PR5 | |
| SCHEMBL3042238 | 0.73 | S1PR5 (1.00) | S1PR1S1PR5HTR2AKCNH2SIGMAR1 | |
| SCHEMBL16722437 | 0.72 | S1PR5 (0.54) | S1PR1S1PR5 | |
| SCHEMBL3040582 | 0.72 | S1PR5 (0.69) | S1PR1S1PR5HTR2AKCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142662-A1 | NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142662-A1 | NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR5 3/4885HTR2A 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.